Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting
Presentations highlight potential of losmapimod to slow or stop progression of FSHD Company on track to initiate Phase 3 REACH...
Month: April 2022
Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting
Two poster presentations highlight Phase 1 data for LP352 in healthy volunteersSAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Longboard...
BioCorRx Provides 2021 Year-End Business Update
ANAHEIM, CA, April 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of...
Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
MIAMI, April 01, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently...
Simply Better Brands Corp. Announces Acquisition of The BRN Group Inc.
VANCOUVER, British Columbia, April 01, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. (the "Company" or “Simply Better Brands”) (TSX...
Integra LifeSciences to Host First Quarter 2022 Financial Results Conference Call on April 27, 2022
PRINCETON, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will...
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused...
Brain Scientific Announces Fourth Quarter and Full Year 2021 Results
LAKEWOOD Ranch, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Brain Scientific (OTCQB: BRSF), an innovative company focusing...
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared...
Enzo Biochem Adjourns Annual Meeting of Shareholders Until April 8, 2022
NEW YORK, NY, April 01, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading...
Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results
CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on...
Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development...
Smart for Life Announces FY 2021 Financial Results
Company Achieves 360% Increase in Revenue in 2021 through Implementation of Successful Acquisition Strategy Completed Three Material Acquisitions in Last...
InnerScope Hearing Technologies (OTC: INND) Posts 2021 Annual Report
Highlights Include $7,266,146 Increase in Shareholder EquityROSEVILLE, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- InnerScope Hearing Technologies Inc. (OTC: INND)...
Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021
LAWRENCEVILLE, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation...
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy
SAN FRANCISCO, April 01, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the...
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
Announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platformMALVERN, Pa., April 01, 2022 (GLOBE NEWSWIRE) --...
Milestone Scientific Reports 90% Year-Over-Year Revenue Growth and Provides 2021 Year-End Business Update
ROSELAND, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery...
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
The Company also announces completion of enrollment in 12-week, Phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver...
ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022
RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the...
